These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 10771553)

  • 1. [A reply: the benefit is marginal--money can be used better].
    Lindroth M
    Lakartidningen; 2000 Mar; 97(11):1302-3. PubMed ID: 10771553
    [No Abstract]   [Full Text] [Related]  

  • 2. [The value of RSV-prophylaxis: the shortage of data must not result in hasty decisions].
    Hansen MV
    Lakartidningen; 2000 Mar; 97(11):1300-2. PubMed ID: 10771552
    [No Abstract]   [Full Text] [Related]  

  • 3. Comment and reply on: The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis.
    Robinson JL
    Curr Med Res Opin; 2009 Jul; 25(7):1631-2; author reply 1632-3. PubMed ID: 19480611
    [No Abstract]   [Full Text] [Related]  

  • 4. [Prevention of respiratory syncytial virus infection by SYNAGIS (palivizumab)].
    Pin I; Pilenko C; Bost M
    Allerg Immunol (Paris); 2002 Dec; 34(10):371-4. PubMed ID: 12575622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit.
    McCormick J; Tubman R
    Pediatr Pulmonol; 2002 Oct; 34(4):262-6. PubMed ID: 12205567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Will we ever say no? For example to the RSV prophylaxis?].
    Lindroth M
    Lakartidningen; 2000 Jan; 97(3):208-9. PubMed ID: 10687354
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus.
    Meissner HC; Bocchini JA; Brady MT; Hall CB; Kimberlin DW; Pickering LK
    Pediatrics; 2009 Dec; 124(6):1676-9. PubMed ID: 19948632
    [No Abstract]   [Full Text] [Related]  

  • 8. Indirect costs of respiratory syncytial virus hospitalizations: a commentary.
    Marks AS
    Value Health; 2003; 6(2):98-9. PubMed ID: 12641859
    [No Abstract]   [Full Text] [Related]  

  • 9. Nosocomial respiratory syncytial virus: a threat in the modern neonatal intensive care unit.
    Heerens AT; Marshall DD; Bose CL
    J Perinatol; 2002 Jun; 22(4):306-7. PubMed ID: 12032794
    [No Abstract]   [Full Text] [Related]  

  • 10. [Prophylaxis of respiratory syncytial virus infections with palivizumab].
    Danés Carreras I; Arnau De Bolós JM
    An Esp Pediatr; 2002 Apr; 56(4):289-91. PubMed ID: 11927094
    [No Abstract]   [Full Text] [Related]  

  • 11. [Is it smart to give immunoglobulin prophylaxis against respiratory syncytial virus infection?].
    Greisen G
    Ugeskr Laeger; 2001 Nov; 163(47):6607. PubMed ID: 11760548
    [No Abstract]   [Full Text] [Related]  

  • 12. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
    Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
    Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 2009 COID recommendations for RSV prophylaxis: issues of efficacy, cost, and evidence-based medicine.
    Krilov LR; Weiner LB; Yogev R; Fergie J; Katz BZ; Henrickson KJ; Welliver RC
    Pediatrics; 2009 Dec; 124(6):1682-4. PubMed ID: 19948634
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
    Mahadevia PJ; Malinoski FJ
    Arch Pediatr Adolesc Med; 2007 May; 161(5):519-20; author reply 520. PubMed ID: 17485634
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost estimates of prophylaxis.
    Moler F
    Arch Pediatr Adolesc Med; 2001 Feb; 155(2):199-200. PubMed ID: 11177100
    [No Abstract]   [Full Text] [Related]  

  • 16. [Respiratory syncytial virus infections and preventive options].
    Moll HA; de Groot R
    Ned Tijdschr Geneeskd; 2000 Apr; 144(15):724-5. PubMed ID: 10778722
    [No Abstract]   [Full Text] [Related]  

  • 17. Neonatal intensive care: cost-benefit analysis.
    Pediatrics; 1985 Apr; 75(4):798-800. PubMed ID: 3920640
    [No Abstract]   [Full Text] [Related]  

  • 18. Health economics and RSV.
    Carbonell-Estrany X; Lázaro y de Mercado P
    Paediatr Respir Rev; 2009 Jun; 10 Suppl 1():12-3. PubMed ID: 19651392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive care unit admission rates for respiratory syncytial virus infection as a function of age in preterm infants born at 32-35-week gestation and not receiving immunoprophylaxis.
    Simões EA; Ambrose CS; Wu X; Anderson EJ
    Pediatr Infect Dis J; 2015 Mar; 34(3):331. PubMed ID: 25742086
    [No Abstract]   [Full Text] [Related]  

  • 20. Experience with the use of palivizumab together with infection control measures to prevent respiratory syncytial virus outbreaks in neonatal intensive care units.
    Kurz H; Herbich K; Janata O; Sterniste W; Bauer K
    J Hosp Infect; 2008 Nov; 70(3):246-52. PubMed ID: 18799241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.